External funding dependence
The company is in a start-up phase and relies on new capital to continue operations and growth plans.
- Scope
- Corporate funding and working capital
- Materiality
- high
Simris Group
Simris Group is a Swedish biologics company focused on identifying and commercialising natural bioactive compounds from microalgae and cyanobacteria. Its work spans discovery, extraction and development of compounds for use in biopharmaceuticals, dietary supplements and cosmetics, with shares listed on Nasdaq First North Growth Market in Sweden.
| % | |
|---|---|
| Biopharma payloads | 45% Natural compounds and payload candidates developed for antibody-drug conjugates and oncology applications. |
| Dietary supplements | 25% Omega-3 and other supplement products and ingredients sold through distributors and direct channels. |
| Cosmetic ingredients | 10% Bioactive natural ingredients intended for use in cosmetic formulations. |
| Research and development services | 20% Preclinical studies, screening and development work around proprietary cyanobacterial compounds. |
Simris Group serves pharmaceutical and biotech counterparties interested in novel payloads for targeted cancer...
- Biopharmaceutical partnersprimary
Buy or evaluate ADC payload candidates and preclinical data for oncology programs.
- Research organizations and CROsprimary
Support in vitro and in vivo studies of proprietary compounds and payload platforms.
- Supplement distributorssecondary
Purchase omega-3 supplement products for resale through retail and online channels.
- Cosmetics ingredient buyerssecondary
Source natural bioactive ingredients for formulation into cosmetic products.
Simris Group is headquartered in Sweden and is listed on Nasdaq First North Growth Market in Stockholm...
- •Sweden is the corporate and operational base
- •Nasdaq First North Growth Market is the listing venue
- •European partners are important for research and collaboration
- •Hammenhög is the main production asset referenced in reports
- •International business development broadens market reach
Simris Group is concentrating on proprietary cyanobacteria-derived payloads for antibody-drug conjugates and related...
01
Advance ADC payload developmentshort-term
Proprietary payload science is the core value driver and differentiator.
02
Secure partnerships and validationshort-term
External validation and collaboration are needed to convert science into commercial value.
03
Optimize asset footprintmedium-term
The production asset base must align with capital availability and strategic focus.
Simris Group faces the typical risks of an early-stage biotech company: scientific uncertainty, long development...
Scientific and development risk
ADC payload programs depend on preclinical results, technical validation and eventual partner interest.
- Scope
- Microcystin payload platform
- Materiality
- high
Asset divestment execution risk
The Hammenhög sale process may take time, fail, or close below expectations.
- Scope
- Production facility and related assets
- Materiality
- medium
Commercialization risk in supplements
Consumer supplement sales have been de-emphasized and may not provide meaningful scale.
- Scope
- Omega-3 supplement channel
- Materiality
- medium
Development cost treatment
Reported operating result and intangible assets
Asset impairment and disposal
Balance sheet carrying values and gain/loss on disposal
Convertible related-party loans
Liabilities, finance costs and share count
Related-party disclosures
Governance and note transparency
: 11/08/2026